首页> 美国卫生研究院文献>Archives of Neuropsychiatry >Effective INR Level May Be Delayed in Secondary Prevention of Stroke Due to Atrial Fibrillation with Warfarin in the Patients with Diabetes Mellitus
【2h】

Effective INR Level May Be Delayed in Secondary Prevention of Stroke Due to Atrial Fibrillation with Warfarin in the Patients with Diabetes Mellitus

机译:糖尿病患者华法林引起的房颤继发性卒中的二级预防可能会延迟有效INR水平

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Warfarin is a drug used for anticoagulation in diseases, especially atrial fibrillation (AF). The effectiveness of warfarin is monitored by the International Normalized Ratio (INR) and should be kept between 2.0 and 3.0 in the AF clinic. This drug the significant variability in dose response and the narrow therapeutic index among individuals. However, the effective INR level may not be achieved due to some reasons, or the time to achieve the effective INR level may lengthen. Our aim in this study is to investigate whether there is a difference in terms of dose and duration in achieving the effective INR level by the warfarin treatment due to the coexistence of AF and stroke between patients with and without diabetes mellitus (DM).
机译:华法林是一种用于疾病,尤其是房颤(AF)的抗凝药物。华法林的有效性通过国际标准化比率(INR)进行监控,在AF诊所中应保持在2.0和3.0之间。该药物在剂量反应中具有显着的可变性,并且个体之间的治疗指数狭窄。但是,由于某些原因可能无法达到有效INR水平,或者达到有效INR水平的时间可能会延长。我们在这项研究中的目的是研究在有和没有糖尿病(DM)的患者中,由于房颤和中风并存,通过华法林治疗达到有效INR水平在剂量和持续时间方面是否存在差异。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号